These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25802762)

  • 1. Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients.
    Vaishampayan U; Thakur A; Rathore R; Kouttab N; Lum LG
    Prostate Cancer; 2015; 2015():285193. PubMed ID: 25802762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial.
    Lum LG; Thakur A; Al-Kadhimi Z; Colvin GA; Cummings FJ; Legare RD; Dizon DS; Kouttab N; Maizel A; Colaiace W; Liu Q; Rathore R
    Clin Cancer Res; 2015 May; 21(10):2305-14. PubMed ID: 25688159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.
    Davol PA; Smith JA; Kouttab N; Elfenbein GJ; Lum LG
    Clin Prostate Cancer; 2004 Sep; 3(2):112-21. PubMed ID: 15479495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
    Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
    Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells.
    Yankelevich M; Thakur A; Modak S; Chu R; Taub J; Martin A; Schalk DL; Schienshang A; Whitaker S; Rea K; Lee DW; Liu Q; Shields A; Cheung NK; Lum LG
    Res Sq; 2023 Nov; ():. PubMed ID: 37986911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.
    Zitron IM; Thakur A; Norkina O; Barger GR; Lum LG; Mittal S
    BMC Cancer; 2013 Feb; 13():83. PubMed ID: 23433400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.
    Lum LG; Al-Kadhimi Z; Deol A; Kondadasula V; Schalk D; Tomashewski E; Steele P; Fields K; Giroux M; Liu Q; Flaherty L; Simon M; Thakur A
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34117114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients.
    Lum LG; Thakur A; Choi M; Deol A; Kondadasula V; Schalk D; Fields K; Dufrense M; Philip P; Dyson G; Aon HD; Shields AF
    Oncoimmunology; 2020 Jun; 9(1):1773201. PubMed ID: 32939319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.
    Ma J; Han H; Liu D; Li W; Feng H; Xue X; Wu X; Niu G; Zhang G; Zhao Y; Liu C; Tao H; Gao B
    PLoS One; 2013; 8(8):e73261. PubMed ID: 24015299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.
    Sen M; Wankowski DM; Garlie NK; Siebenlist RE; Van Epps D; LeFever AV; Lum LG
    J Hematother Stem Cell Res; 2001 Apr; 10(2):247-60. PubMed ID: 11359672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study.
    Thakur A; Scholler J; Schalk DL; June CH; Lum LG
    J Cancer Res Clin Oncol; 2020 Aug; 146(8):2007-2016. PubMed ID: 32449004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1
    Lum LG; Thakur A; Elhakiem A; Alameer L; Dinning E; Huang M
    Front Oncol; 2020; 10():544. PubMed ID: 32432032
    [No Abstract]   [Full Text] [Related]  

  • 13. Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo.
    Han H; Ma J; Zhang K; Li W; Liu C; Zhang Y; Zhang G; Ma P; Wang L; Zhang G; Tao H; Gao B
    Int J Oncol; 2014 Dec; 45(6):2446-54. PubMed ID: 25242665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.
    Lum LG; Thakur A; Liu Q; Deol A; Al-Kadhimi Z; Ayash L; Abidi MH; Pray C; Tomaszewski EN; Steele PA; Schalk DL; Yano H; Mitchell A; Dufresne M; Uberti JP; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):925-33. PubMed ID: 23529012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer.
    Vaishampayan UN; Thakur A; Chen W; Deol A; Patel M; Dobson K; Dickow B; Schalk D; Schienschang A; Whitaker S; Polend A; Fontana JA; Heath EI; Lum LG
    Clin Cancer Res; 2023 Jan; 29(1):122-133. PubMed ID: 36255393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study.
    Lum LG; Thakur A; Pray C; Kouttab N; Abedi M; Deol A; Colaiace WM; Rathore R
    Bone Marrow Transplant; 2014 Jan; 49(1):73-9. PubMed ID: 24056738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.
    Yu S; Liu Q; Han X; Qin S; Zhao W; Li A; Wu K
    Exp Hematol Oncol; 2017; 6():31. PubMed ID: 29209558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune T cells can transfer and boost anti-breast cancer immunity.
    Thakur A; Rathore R; Kondadasula SV; Uberti JP; Ratanatharathorn V; Lum LG
    Oncoimmunology; 2018; 7(12):e1500672. PubMed ID: 30524893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
    Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.
    Yankelevich M; Thakur A; Modak S; Chu R; Taub J; Martin A; Schalk D; Schienshang A; Whitaker S; Rea K; Lee DW; Liu Q; Shields AF; Cheung NV; Lum LG
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.